论文部分内容阅读
作者在一些疾病中测定了βTG、PF_4和Thrombospoadin(TSP),分析这三种作为体内血小板释放增强的指标所具有的价值。这是一些以往已证明有血浆βTG和/或PF_4增高的疾病,包括骨髓增生性疾病(MPFD,n=13)、白血病(LE,n=34)、糖尿病(MD,n=31)、作全髋置换术(Total Hip Replacement,THR)的病人(n=33),还有急性和慢性肝功衰(ALF,n=12;CLF,n=9)以及肾功衰患者(RF)。后者分三组:A组(RFa)18人,病情稍轻,无需作血液透析;B组(RFb)22人,常需作血液透析;C组(RFc)5人,选自RFb,在肝素化条件下作血液透析,以防止体内纤维蛋白形成。用常规放射免疫测
The authors determined βTG, PF_4, and Thrombospoadin (TSP) in several diseases and analyzed the value of these three as an indicator of increased platelet release in vivo. Here are some of the diseases that have previously been shown to have elevated plasma βTG and / or PF 4, including myeloproliferative disorders (MPFD, n = 13), leukemia (LE, n = 34), and diabetes mellitus (n = 31) Patients with total hip replacement (THR) (n = 33) also had acute and chronic liver failure (ALF, n = 12; CLF, n = 9) and patients with renal failure (RF). The latter were divided into three groups: 18 patients in group A (RFa), slightly ill, without hemodialysis; 22 patients in group B (RFb), often requiring hemodialysis; 5 patients in group C (RFc) Heparinized for hemodialysis to prevent the formation of fibrin in vivo. Routine radioimmunoassay